Celltrion Inc
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- $31.9B
- Website
- http://www.celltrion.com/
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
Phase 1
Completed
- Conditions
- Ulcerative Colitis (Part 2 Only)Crohn's Disease
- Interventions
- Biological: CT-P13
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 181
- Registration Number
- NCT02883452
- Locations
- 🇰🇷
Yeungnam University Hospital, Daegu, Korea, Republic of
Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 70
- Registration Number
- NCT02665637
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
An Observational Study to Evaluate Safety and Efficacy of Remsimaâ„¢ in Patients With RA
Terminated
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 248
- Registration Number
- NCT02557295
An Observational Study to Evaluate Safety and Efficacy of Remsimaâ„¢ in Patients With Ankylosing Spondylitis
Terminated
- Conditions
- Ankylosing Spondylitis
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 329
- Registration Number
- NCT02557308
- Locations
- 🇰🇷
TaeHwan Kim, Seoul, Korea, Republic of
To Evaluate the Safety and Efficacy of Remsimaâ„¢ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)
Terminated
- Conditions
- Ulcerative ColitisCrohn's Disease
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 470
- Registration Number
- NCT02326155
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Phase 3
Completed
- Conditions
- Follicular Lymphoma
- Interventions
- Biological: CT-P10Biological: Rituxan
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 258
- Registration Number
- NCT02260804
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan
Phase 3
Completed
- Conditions
- Lymphoma, Follicular
- Interventions
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 140
- Registration Number
- NCT02162771
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 562
- Registration Number
- NCT02162667
PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 384
- Registration Number
- NCT02149121
Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
Phase 3
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: CT-P13Biological: Remicade
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 220
- Registration Number
- NCT02096861
- Locations
- 🇺🇸
Nashville Medical Research Institute, Nashville, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath